236 related articles for article (PubMed ID: 3891854)
41. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
Lafreniere R; Rosenberg SA
Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
[TBL] [Abstract][Full Text] [Related]
42. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
Mulé JJ; Shu S; Rosenberg SA
J Immunol; 1985 Jul; 135(1):646-52. PubMed ID: 3889158
[TBL] [Abstract][Full Text] [Related]
43. Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: a new approach to the adoptive immunotherapy of cancer.
Rosenberg SA; Eberlein TJ; Grimm EA; Lotze MT; Mazumder A; Rosenstein M
Surgery; 1982 Aug; 92(2):328-36. PubMed ID: 6980492
[TBL] [Abstract][Full Text] [Related]
44. Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors.
Papa MZ; Yang JC; Vetto JT; Shiloni E; Eisenthal A; Rosenberg SA
Cancer Res; 1988 Jan; 48(1):122-9. PubMed ID: 3257159
[TBL] [Abstract][Full Text] [Related]
45. Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody.
Kim JA; Bresler HS; Martin EW; Aldrich W; Heffelfinger M; Triozzi PL
Cancer; 1999 Jul; 86(1):22-30. PubMed ID: 10391559
[TBL] [Abstract][Full Text] [Related]
46. Cytotoxic NK1.1 Ag+ alpha beta T cells with intermediate TCR induced in the liver of mice by IL-12.
Hashimoto W; Takeda K; Anzai R; Ogasawara K; Sakihara H; Sugiura K; Seki S; Kumagai K
J Immunol; 1995 May; 154(9):4333-40. PubMed ID: 7722291
[TBL] [Abstract][Full Text] [Related]
47. Effect of albumin fusion on the biodistribution of interleukin-2.
Yao Z; Dai W; Perry J; Brechbiel MW; Sung C
Cancer Immunol Immunother; 2004 May; 53(5):404-10. PubMed ID: 14624312
[TBL] [Abstract][Full Text] [Related]
48. Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice.
Gately MK; Anderson TD; Hayes TJ
J Immunol; 1988 Jul; 141(1):189-200. PubMed ID: 3259967
[TBL] [Abstract][Full Text] [Related]
49. Intradermal delivery of IL-12 naked DNA induces systemic NK cell activation and Th1 response in vivo that is independent of endogenous IL-12 production.
Watanabe M; Fenton RG; Wigginton JM; McCormick KL; Volker KM; Fogler WE; Roessler PG; Wiltrout RH
J Immunol; 1999 Aug; 163(4):1943-50. PubMed ID: 10438930
[TBL] [Abstract][Full Text] [Related]
50. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
[TBL] [Abstract][Full Text] [Related]
51. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice.
Berman RM; Suzuki T; Tahara H; Robbins PD; Narula SK; Lotze MT
J Immunol; 1996 Jul; 157(1):231-8. PubMed ID: 8683120
[TBL] [Abstract][Full Text] [Related]
52. In vivo activation of natural killer cells and priming of IL-2 responsive cytolytic cells by loxoribine (7-allyl-8-oxoguanosine).
Pope BL; Chourmouzis E; Sigindere J; MacIntyre JP; Capetola RJ; Lau CY
Cell Immunol; 1993 Apr; 147(2):302-12. PubMed ID: 8453674
[TBL] [Abstract][Full Text] [Related]
53. FLT3-ligand administration inhibits liver metastases: role of NK cells.
Péron JM; Esche C; Subbotin VM; Maliszewski C; Lotze MT; Shurin MR
J Immunol; 1998 Dec; 161(11):6164-70. PubMed ID: 9834102
[TBL] [Abstract][Full Text] [Related]
54. Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth.
Forni G; Giovarelli M; Santoni A
J Immunol; 1985 Feb; 134(2):1305-11. PubMed ID: 3871210
[TBL] [Abstract][Full Text] [Related]
55. Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: implications for anti-cancer and anti-viral therapy.
Shaw SG; Maung AA; Steptoe RJ; Thomson AW; Vujanovic NL
J Immunol; 1998 Sep; 161(6):2817-24. PubMed ID: 9743341
[TBL] [Abstract][Full Text] [Related]
56. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.
Lotze MT; Matory YL; Ettinghausen SE; Rayner AA; Sharrow SO; Seipp CA; Custer MC; Rosenberg SA
J Immunol; 1985 Oct; 135(4):2865-75. PubMed ID: 2993418
[TBL] [Abstract][Full Text] [Related]
57. Rapid and specific targeting of 125I-labeled B lymphocyte stimulator to lymphoid tissues and B cell tumors in mice.
Riccobene TA; Miceli RC; Lincoln C; Knight Y; Meadows J; Stabin MG; Sung C
J Nucl Med; 2003 Mar; 44(3):422-33. PubMed ID: 12621010
[TBL] [Abstract][Full Text] [Related]
58. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
59. Limiting dilution analysis of the frequency of human T cells and large granular lymphocytes proliferating in response to interleukin 2. I. The effect of lectin on the proliferative frequency and cytotoxic activity of cultured lymphoid cells.
Vose BM; Bonnard GD
J Immunol; 1983 Feb; 130(2):687-93. PubMed ID: 6600251
[TBL] [Abstract][Full Text] [Related]
60. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
